Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Hoth Therapeutics, OnTargetx R&D Partner to Advance Research for Cancer Therapeutic | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Hoth Therapeutics, OnTargetx R&D Partner to Advance Research for Cancer Therapeutic

Will conduct an immunohistochemistry study to accelerate HT-KIT.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Hoth Therapeutics Inc., a biopharmaceutical company committed to developing innovative therapies for unmet medical needs, has collaborated with OnTargetx R&D Inc. to accelerate research for its cancer-fighting therapeutic, HT-KIT.

HT-KIT, Hoth’s preclinical therapeutic candidate, targets c-Kit, a receptor tyrosine kinase implicated in numerous cancers. This candidate holds the potential to revolutionize precision oncology therapies.

This immunohistochemistry study, conducted in partnership with Charles River Laboratories Montreal ULC, represents a key step in the preclinical development of HT-KIT and aligns with Hoth Therapeutics’ mission to accelerate groundbreaking therapies and address unmet medical needs in oncology.

The study focuses on:

  • Development and optimization of staining methods for (c-Kit) markers, a critical target in HT-KIT therapeutic mechanism.
  • Processing and qualitative evaluation of tissue samples by a board-certified pathologist to determine the presence of markers.
  • Comprehensive reporting and insights to support the continued development of HT-KIT.

“This partnership is instrumental in our efforts to advance HT-KIT, a promising therapeutic aimed at targeting c-Kit in cancer treatments,” said Robb Knie, CEO at Hoth Therapeutics. “We are committed to driving innovative solutions that can transform patient care.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics